Ludovic Trefond

[Donald Thomas, MD @lupuscyclopedia]

#SLE #lupus patients, doctors, nurses, NPs, PAs: take this short survey from Dr. @LudovicTrefond about "Difficult-To-Control Lupus." What do you consider to be important in the definition?:

https://t.co/NmIlpmhYHw

[RMD Open @bmj_rmdopen]

🦫 Hyposplenism in SLE: an underrecognised risk factor for severe infections
📊 9.4% of 245 SLE patients had Howell-Jolly bodies on blood smear
📈 7x higher risk of infection-related hospitalisation (OR 7.3)
⚠️ Pneumococcal infections: 21.7% vs 0.5% in non-hyposplenism
🔗 Key associations: paediatric-onset SLE (OR 5.2), antiphospholipid syndrome (OR 6.8)
🔗 https://t.co/8x6T88Kx3L

[Ludovic Trefond @LudovicTrefond]

Happy to share our work on Hyposplenism in systemic lupus erythematosus: biological and radiological characteristics and its association with increased risk of infection

https://t.co/Gn99unD0o4

[Ludovic Trefond @LudovicTrefond]

2ème Journée Annuelle du Centre de Référence Constitutif des Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares d’Auvergne #Lupus #SLE #maladiesrares #cartcells #chuclermontferrand

[Ludovic Trefond @LudovicTrefond]

Hydroxychloroquine in systemic lupus erythematosus: Key updates
https://t.co/xqNYRXg47n

[Ludovic Trefond @LudovicTrefond]

The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: A large pooled post hoc analysis https://t.co/4o51B6dOMj

[NEJM @NEJM]

Original Article: Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis (REGENCY trial) https://t.co/MyUTlfB8nE

#ISNWCN | @ISNWCN

[Kaleidoscope Fighting Lupus @Kaleidoscope_FL]

Lupus in the News: A recent study found that valaciclovir (Valtrex) was very effective at preventing herpes zoster virus (shingles) in lupus patients who also take anifrolumab (Saphnelo) - a potential alternative to the shingles vaccine.

Link to study: https://t.co/ArO8tJMgwf

[RMD Open @bmj_rmdopen]

📢 New study highlights herpes zoster (HZ) prevention in SLE patients treated with anifrolumab
💡SLE patients on anifrolumab face increased HZ risk, especially in the first year
🔬Prophylactic valaciclovir ⬇️ HZ incidence significantly (HR 0.08, p=0.01)
🔑 https://t.co/WOOpPSkTml

[Dr. John Cush @RheumNow]

Anti-Zoster Drug Prevents Shingles in Lupus Patients on Anifrolumab

The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with SLE under treatment with anifrolumab (Saphnelo) from having herpes zoster attacks, researchers said, offering a potential alternative to zoster vaccination.

https://t.co/qb7h6BuCz3

[Ludovic Trefond @LudovicTrefond]

Happy to share our collaborative work with French colleagues on preventing herpes zoster in patients receiving Anifrolumab #SLE #Lupus #Anifrolumab #HerpesZoster

https://t.co/yOXEJkyKhg

[George Bertsias @george_bertsias]

Happy to share our collaborative work with friends and colleagues from Ferrara https://t.co/zVCPNkFiyc

[Ludovic Trefond @LudovicTrefond]

#XeJournéeFrançaiseduLupusSystémique #lupus #hydroxychloroquine

[Donald Thomas, MD @lupuscyclopedia]

🔥 Excellent article on flares after #COVID vaccines in 7336 patients with systemic autoimmune diseases like #lupus #SLE #Sjogrens by @pedrommcmachado and other colleagues of the EULAR COVAX Registry #COVAX:

CLICK👉 https://t.co/l45OpVLjmy

Some take away points:

- Overall 4% of patients flared
- Of those with a connective tissue disease (CTD) like lupus etc, half of those who flared needed medication adjustments
- 97% of CTD patients did NOT flare (VERY IMPORTANT number to keep in mind)
- CTD patients who were in remission were less likely to flare
- Patients on methotrexate were less likely to flare
- Stopping immunosuppressants to improve efficacy of the vaccine was more likely to be associated with flares (but most who stopped meds did not flare)
- The vast majority of flares were mild to moderate severity in CTD patients
- 0.5% of all CTD vaccinated patients had a severe flare (around one out of every 200 vaccinated CTD patients)

When making a decision on medical treatment (such as vaccines) it should be a decision on the risk of adverse events (like severe flare) vs benefit.

With the above data, I'll continue to highly recommend vaccination for my patients. I've seen too many deaths in my immunosuppressed patients from COVID (as recently as a few months ago).

However, in those who are not in remission, I'd discuss the possibility of not holding medications at the time of the vaccine (much less likely to flare if medications are not stopped), which would reduce the risk of flare, vs holding immunosuppressants to improve the effectiveness of the vaccine.

Bottom Line: Vaccinations are a personal choice. Do what you feel is best for your body.

@ARD_BMJ

[Fulvia Ceccarelli @FulviaCeccarell]

Proud to have participated in the #Advance2024 event and for the opportunity to interact with leading #Lupus experts.

[Jerome HADJADJ @HadjadjJerome]

Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus
https://t.co/kLLPU82X6F

[Filière de santé FAI²R @contactfai2r]

🔔 RDV le 18 décembre pour la Journée Française du Lupus Systémique !

📍 À l’ICM de La Pitié-Salpêtrière ou 💻 via Zoom

📋 Inscription gratuite : [email protected]

+ d'infos : https://t.co/Twkb0UHF8D

#Lupus #Santé #Médecine

[Kaleidoscope Fighting Lupus @Kaleidoscope_FL]

Lupus Nephritis in the News: Gazyva (obinutuzumab), a biologic used to treat cancers, has successfully achieved Phase 3 trial results for lupus nephritis (LN) - and could give LN patients another option with FDA approval!

Link: https://t.co/anmLy8JXIv

[The Lancet Rheumatology @TheLancetRheum]

NEW in @LancetChildAdol—A nationwide study reports the first epidemiological data on childhood-onset systemic #lupus erythematosus in #China, 2016–21 https://t.co/9X3nONUnK5 #SLE

[Annals of the Rheumatic Diseases @eular_ARD]

In the Sept issue ▶️ #APS #SLE by #transcriptomeanalysis 🦋
❇️ #IFN I-II signature ▶️ highest in SLE-aPL-negative
🔵 Venous ▶️ neutrophils & B cells
🔴 Arterial ▶️ DNA-damage-response & impaired metabolism
🔗 https://t.co/vPVv6gcGLg
@DionysisNik @george_bertsias @IoannisParodis